Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer and Onyx kidney cancer drug ups survival rate 39 per cent

Bayer and Onyx kidney cancer drug ups survival rate 39 per cent

8th November 2005

A drug designed to help kidney cancer suffers has improved survival rates by over a third.

Sorafenib, developed jointly by pharmaceutical companies Bayer and Onyx, was tested in a trial involving 900 kidney cancer patients. Half of the patients were given the drug twice daily, whilst the other half were offered a placebo.

The study found that the Sorafenib had improved the chance of survival by 39 per cent. Interim results allowed those who had been taking the placebo to “crossover” to the drug in April, after the companies took the decision based on ethnic considerations.

“These data build on the previously announced finding that disease progression was significantly delayed in advanced kidney cancer patients who received Sorafenib,” said Dr Bernard Escudier, speaking to the European Cancer Conference.

“As a clinician who regularly sees individuals suffering from this disease, I am encouraged by this growing body of data and what they may mean for patients and their families,” he added.

The study had also found that the drug had caused tumour shrinkage in 74 per cent of patients, compared to 20 per cent of those taking placebos.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.